About
Palladio Biosciences is developing lixivaptan, a drug in Phase 3 clinical trials aimed at treating autosomal dominant polycystic kidney disease (ADPKD), a chronic kidney condition characterized by fluid-filled cysts.
Explore Palladio Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.